ENvue Medical Expands Presence within a Major Michigan Health System and Grows U.S. Hospital Footprint to 39
MWN-AI** Summary
ENvue Medical, Inc. (NASDAQ: FEED), a Texas-based medical technology company, has announced a significant expansion of its services within the healthcare sector by partnering with a major teaching hospital and Level I Trauma Center in the Detroit metropolitan area. This partnership involves the acquisition of the ENvue™ Navigation Platform and feeding tubes, which enhances ENvue's U.S. hospital footprint to 39 hospitals, solidifying its position in the market for intelligent, non-invasive enteral care solutions.
The newly partnered facility is a 714-bed hospital known for its comprehensive specialty institutes, including oncology, cardiovascular care, and pediatrics. It operates critical care environments, including multiple intensive care units, making it a fitting location for ENvue's innovative technologies aimed at improving workflow efficiency and patient safety.
ENvue’s Vice President of Commercial, Marc Waldman, expressed enthusiasm for the partnership, highlighting the increasing trend among hospitals to seek advanced technologies that enhance clinical workflows while addressing cost containment strategies. Dr. Doron Besser, ENvue's CEO, reiterated this sentiment, noting that hospitals are prioritizing real-time visualization and standardization in feeding tube placement practices—a crucial aspect of patient care that ENvue's technology aims to support.
The ENvue™ Navigation Platform is designed to integrate seamlessly into existing clinical workflows and offers real-time bedside visualization of tube movement, thereby aiding healthcare professionals in making informed decisions during feeding tube placements. The company's commitment to patient safety and clinical usability lays the groundwork for potential future expansion into pediatric and vascular access applications.
This expansion aligns with ENvue Medical's mission to transform enteral care by leveraging innovative medical technologies across clinical and home care environments.
MWN-AI** Analysis
ENvue Medical's recent expansion within a major Michigan health system marks a significant milestone for the company, now operating across 39 U.S. hospitals. This growth is particularly noteworthy given the increasing demand for innovative medical technologies aimed at improving workflow efficiency and patient safety. ENvue’s navigation platform provides real-time visualization during feeding tube placements, addressing critical needs in clinical environments, particularly within critical care units.
For investors and analysts, this announcement presents an effective narrative for ENvue Medical’s potential growth. The company’s focus on multi-faceted expansion strategies, as emphasized by executives, signals a commitment to establishing a foothold in an evolving healthcare landscape. Given the increasing emphasis on non-invasive solutions in enteral care, ENvue's technology aligns with broader healthcare trends focusing on patient-centric care advancements.
However, while the outlook appears promising, investors should maintain a cautious approach. The medical device industry is notoriously competitive, and ENvue must navigate various risks, including reimbursement challenges and regulatory changes. Thus, it’s essential for investors to monitor how well ENvue addresses these pressures as it scales its operations.
Furthermore, the strategic partnerships within reputable teaching hospitals can enhance credibility and may pave the way for broader adoption of its products. As ENvue looks to deploy its technology in more healthcare environments, maintaining performance excellence and ensuring seamless integration will be key.
In summary, while ENvue Medical is well-positioned for growth, potential investors should remain vigilant, keeping an eye on both the opportunities and the challenges this company faces in the dynamic medical technology market. The advancement of its Navigation Platform, combined with careful market execution, could yield a promising investment opportunity if managed effectively.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
TYLER, Texas, March 24, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings, today announced a purchase of the ENvue™ Navigation Platform and feeding tubes by a premier teaching hospital and Level I Trauma Center serving the Detroit metropolitan area. The purchase expands ENvue’s presence within a major Southeast Michigan health system where the Company has previously been deployed, and brings ENvue’s U.S. hospital footprint to 39 hospitals.
The facility is a 714-bed major teaching hospital and a key anchor of a leading regional health system. It is known for comprehensive specialty institutes in oncology, cardiovascular care, and pediatrics, and operates a broad network of critical care environments, including medical, pediatric, surgical, and cardiovascular intensive care units (ICUs), as well as a dedicated Level III Neuro-ICU.
“We believe that this partnership represents the strategic account expansion we are focused on nationwide,” said Marc Waldman, Vice President of Commercial at ENvue Medical. “Preeminent teaching and non-teaching hospitals alike are seeking innovative technologies that can improve workflow efficiency while supporting cost containment and patient safety initiatives. The ENvue™ Navigation Platform addresses these priorities, and we are encouraged by the increasing demand we are seeing from health systems looking to modernize, standardize and enhance enteral access procedures across their hospitals.”
“Hospitals are increasingly prioritizing real-time visualization and greater standardization in feeding tube placement,” said Doron Besser, MD, Chief Executive Officer of ENvue Medical. “This expansion within a leading Michigan health system reflects continued momentum in our commercial execution for the ENvue™ Navigation Platform. We believe we are continuing to build on our relationship within the system as we expand our footprint to 39 hospitals, and we look forward to supporting broader adoption across additional sites over time.”
ENvue’s Navigation Platform is designed to integrate into existing clinical workflows and is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.
About ENvue Medical, Inc.
ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel, the Company focuses on two distinct technology platforms:
- ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc., with offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.
- ENvue Medical aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a range of healthcare environments.
- Acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.
Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements include but are not limited to: statements regarding the adoption and implementation of ENvue Medical’s platforms, anticipated commercial expansion, growth, scalability, and implementation of ENvue Medical’s products, the success of ENvue’s programs, market interest in the Company’s technology, and future expectations for strategic growth. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company’s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.
Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
envue@kcsa.com
Media Contact:
KCSA Strategic Communications
Raquel Cona, Vice President
PH: (516) 779-2630
envue@kcsa.com
FAQ**
How does the recent purchase of the ENvue™ Navigation Platform by a Detroit teaching hospital impact the growth strategy of ENvue Medical Inc Com Par $0.001 New FEED in the healthcare market?
What specific advantages does the ENvue™ Navigation Platform offer to hospitals that could enhance their workflow efficiency, as highlighted by ENvue Medical Inc Com Par $0.001 New FEED?
Given the company's expansion to hospitals, what are ENvue Medical Inc Com Par $0.001 New FEED's future plans for scaling their technology across additional health systems?
How does ENvue Medical Inc Com Par $0.001 New FEED plan to address potential risks mentioned in their forward-looking statements concerning market acceptance and competition?
**MWN-AI FAQ is based on asking OpenAI questions about ENvue Medical Inc Com Par $0.001 New (NASDAQ: FEED).
NASDAQ: FEED
FEED Trading
20.75% G/L:
$2.56 Last:
18,264,750 Volume:
$2.67 Open:
